Re-evaluation of saliva for monitoring theophylline concentrations

G W RYLANCE, D T BESWICK, R E CULLEN, AND D G V ROBERTS
Children's Hospital, Ladywood Middleway, Birmingham

SUMMARY Variability of the mixed saliva/plasma theophylline relation was examined in seven children aged 2 to 13 years. Good correlation between plasma and saliva concentrations was found, but on the three occasions there was considerable inter- and intrapatient variability. There was no significant or consistent relation between unstimulated and stimulated saliva concentrations or between saliva concentrations and sample volumes. Plasma theophylline concentrations cannot be predicted accurately from saliva values.

Theophylline is an effective bronchodilator for both acute medical treatment and prophylaxis of asthma. Bronchodilator effect and toxicity are closely related to plasma concentration, and optimum treatment in adults is usually achieved when the plasma theophylline concentration is maintained within the range 10 to 20 mg/l (55 to 110 μmol/l). This therapeutic range has not been confirmed in children, although decreased symptoms have been noted in a group of children when concentrations averaged 13 mg/l (67 μmol/l) compared with a mean value below 10 mg/l.

There are large intersubject differences in theophylline pharmacokinetics in children. Plasma theophylline concentrations need to be monitored, therefore, in order to establish the dose required to achieve concentrations within the therapeutic range, which, it is assumed, is equally applicable to children.

Saliva sampling is used to monitor drug concentrations of some anticonvulsants, and its use to monitor theophylline has been suggested. The evidence in the published reports, however, does not always support this view. This study aimed to examine the validity of using saliva for monitoring theophylline by examining the effects on the saliva/plasma theophylline ratio of certain factors known to affect the saliva/plasma relation of drugs generally.

Methods

Seven children aged 2 to 13 years were included in the study, which had been approved by our local research ethical committee: informed parental consent was obtained. None of the children had liver or kidney disease, and none were receiving drugs known to affect theophylline disposition. No attempt was made to minimise dietary xanthines on the day before or during the study periods.

Each child was studied on three separate occasions. Firstly, after a constant rate infusion into a peripheral vein of approximately 3-5 mg/kg aminophylline (79% theophylline, 21% ethylene diamine) over 20 minutes. Two saliva samples (one unstimulated, one stimulated by citric acid crystals) and a venous blood sample (1 ml – via an indwelling heparinised catheter) were obtained before and at hourly intervals for 10 hours after completion of the infusion. Saliva samples were collected in children aged under 4 years by a mucus extractor, and older children were asked to spit into a container until approximately 2 to 4 ml of mixed saliva was collected. Thorough mouth washing took place before and after each sample.

The children were then studied on two subsequent occasions during regular, oral sustained release aminophylline or theophylline treatment given in equal 12 hourly doses at 8 am and 8 pm. Six children received Phyllocontin (Napp Laboratories) and one received Theo Dur (Fisons). Each study was within two weeks and after at least five days of the preceding study, and on each occasion hourly samples (two saliva, one blood as above) were collected between morning and evening doses. The weight related dose increased with time and was different on each occasion within each individual.

The volumes of the saliva samples were measured and the samples centrifuged and stored at −20°C until assayed for theophylline (EMIT (Syva)). The lower limit of the assay was 1-0 mg/l (5-5 μmol/l). The within run and between run coefficients of
Table 1  Relation between unstimulated (UCs) and stimulated (SCs) saliva concentrations, plasma concentrations (Cp), and volumes of samples in children on different dosage regimens of aminophylline

<table>
<thead>
<tr>
<th>Patient</th>
<th>Route</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>Oral</td>
<td>IV</td>
<td>Oral</td>
<td>IV</td>
<td>Oral</td>
<td>IV</td>
<td>Oral</td>
</tr>
<tr>
<td>Dose (mg/kg/dose)</td>
<td>2.7</td>
<td>5.4</td>
<td>10.8</td>
<td>3.2</td>
<td>6.3</td>
<td>12.6</td>
<td>2.8</td>
<td>6.5</td>
</tr>
<tr>
<td>Correlation coefficient UCs v SCs</td>
<td>*</td>
<td>0.49</td>
<td>0.01</td>
<td>0.78</td>
<td>0.25</td>
<td>0.35</td>
<td>*</td>
<td>0.12</td>
</tr>
<tr>
<td>Correlation coefficient Cp v UCs</td>
<td>0.72</td>
<td>0.49</td>
<td>0.62</td>
<td>0.97</td>
<td>0.36</td>
<td>0.60</td>
<td>*</td>
<td>0.74</td>
</tr>
<tr>
<td>UCs (%) Mean (SD)</td>
<td>50.9</td>
<td>53.8</td>
<td>53.5</td>
<td>58.1</td>
<td>49.2</td>
<td>32.2</td>
<td>*</td>
<td>60.6</td>
</tr>
<tr>
<td>Correlation coefficient volume UCs CP v SCs</td>
<td>*</td>
<td>-0.11</td>
<td>-0.35</td>
<td>-0.47</td>
<td>0.62</td>
<td>0.78</td>
<td>*</td>
<td>0.78</td>
</tr>
<tr>
<td>Correlation coefficient CP v SCs</td>
<td>-0.40</td>
<td>0.89</td>
<td>0.51</td>
<td>0.85</td>
<td>0.65</td>
<td>0.68</td>
<td>0.78</td>
<td>0.40</td>
</tr>
<tr>
<td>SCs (%) Mean (SD)</td>
<td>50.8</td>
<td>61.6</td>
<td>39.8</td>
<td>58.5</td>
<td>55.4</td>
<td>42.1</td>
<td>42.3</td>
<td>45.1</td>
</tr>
<tr>
<td>Correlation coefficient volume SCs CP v Cp</td>
<td>0.03</td>
<td>-0.13</td>
<td>-0.22</td>
<td>0.24</td>
<td>0.0</td>
<td>-0.71</td>
<td>0.27</td>
<td>-0.28</td>
</tr>
</tbody>
</table>

*--Sample concentrations <1.0 mg/l (lower limit of assay sensitivity); --- incomplete sample number.
Conversion—traditional units to SI: theophylline 1 mg/l = 5.56 μmol/l.

---

Re-evaluation of saliva for monitoring theophylline concentrations

Re-evaluation of saliva for monitoring theophylline concentrations

---

Results

The results are shown in Table 1. Despite a highly significant correlation between the plasma theophylline concentration (stimulated and unstimulated) (r=0.79, n=22) and saliva theophylline concentration, as shown by the poor and variable correlation coefficients, as shown in Table 1, neither was there any consistent relation between the stimulated saliva/plasma ratio and sample time. The results were also marked inter- and intrasubject variation, and saliva/plasma ratios varied between 32% and 66% (Table 1). There was no significant or consistent relation between the stimulated and unstimulated saliva/plasma ratios, which varied between 5.8% and 25%, as shown in Table 1 (n=10) and 5.8% (χ=15.0 mg/l) respectively.

---

Discussion

Saliva has been substituted for plasma in the therapeutic and pharmacokinetic monitoring of theophylline in children. The results of this study confirm previous reports (Woolley et al., 1980) that saliva concentrations are well related to plasma concentrations. The use of saliva in place of plasma can result in factors such as ease of sample collection, which can improve patient compliance and reduce the risk of traumatic aspiration. The correlation coefficients for saliva and plasma concentrations were found to be significant, but the correlation was poor between saliva and plasma concentrations, as shown in Table 1. The results were consistent with previous studies, and the use of saliva in place of plasma for theophylline monitoring is recommended.
in concentrations indirect means of monitoring plasma ratio. These results show that an assumed volume, therapeutically determined. 

concentration thorough approach, the use of saliva/plasma may be discounted as to any advantage. 

Wider variation within a centre, expertise in collection, and great attention to mouth hygiene and cleansing may be expected to reduce the saliva/plasma variation, one of us (GWR) now has personal experience of collecting over 2000 saliva specimens of different type, and, in spite of a consistent thorough approach, the wide variation is evident in this study.

Variation in plasma protein binding may account for some variation in free fraction and hence the saliva/plasma ratio, but our within patient values are of such magnitude as to almost discount this explanation.

There is no available information on the direct relation between saliva theophylline concentrations and clinical effect. No therapeutic range for saliva theophylline concentration has therefore been determined. In practice saliva concentrations have been used by clinicians as an indirect measure of the plasma drug concentration using the plasma therapeutic range proportionately changed according to an assumed consistent saliva/plasma concentration ratio. These results show that the use of saliva as an indirect means of monitoring plasma theophylline concentrations in children and so forming a basis for dose modification should not become routine practice as the predictive error for plasma concentration is greater than 2 mg/l in over half the samples. In the search for an accurate non-invasive alternative to plasma theophylline concentrations, it will be necessary to determine the relation between the concentrations in the medium used and to devise an optimum therapeutic range for that medium. We question whether the use of mucous extractors, citric acid crystals, and repeated saliva sampling might not prove as invasive as the use of plasma. For repeated sampling, as in kinetic studies, six of our seven patients (those 4 years and over) would prefer the placement of an indwelling intravenous cannula with subsequent drawing of samples through it, to that of repeated saliva stimulation and collection as described here—provided that only one intravenous access is required.

References


Correspondence to Dr G W Rylance, Children’s Hospital, Birmingham B16 8ET.

Received 30 July 1984

Table 2 Relation between saliva type and plasma concentration and the error in predicting plasma concentrations from saliva

<table>
<thead>
<tr>
<th>Sample</th>
<th>No of samples</th>
<th>Correlation coefficient χv plasma concentration</th>
<th>P value</th>
<th>Error in predicting plasma concentration (as % of all predictions)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≤1 mg/l</td>
</tr>
<tr>
<td>Unstimulated saliva</td>
<td>99</td>
<td>0.76</td>
<td>&lt; 0.001</td>
<td>17</td>
</tr>
<tr>
<td>Stimulated saliva</td>
<td>125</td>
<td>0.84</td>
<td>&lt; 0.001</td>
<td>23</td>
</tr>
<tr>
<td>All saliva</td>
<td>224</td>
<td>0.79</td>
<td>&lt; 0.001</td>
<td>16</td>
</tr>
</tbody>
</table>

χv=Concentration of sample type.
Conversion—traditional units to SI: theophylline 1 mg/l=5.56 mmol/l.

Table 2 Relation between saliva type and plasma concentration and the error in predicting plasma concentrations from saliva